Possible Reasons for having a Liver Examination?

FDA-Approved GLP-1 Weight Loss Therapy

Wegovy (semaglutide) injection 2.4 mg is indicated, in combination with a reduced calorie diet and increased physical activity, for:

Treatment of adults with noncirrhotic MASH with moderate to advanced fibrosis (F2–F3). The indication for MASH is approved under accelerated approval based on the improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
Risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
Reduction of excess body weight and maintenance of weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbidity.
Limitations of use: Wegovy contains semaglutide. Coadministration with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended.

The Stealth Threat of MASH
MASH affects approximately 1 in 20 adults, yet 9 out of 10 people living with it remain undiagnosed.

Without intervention, MASH can progress to cirrhosis, liver failure, and higher risk of cardiovascular events and type 2 diabetes.